Manufacturers

ACOBIOM

1682, Rue De La Valsière - Cs77394, Cap Delta - Biopole Euromédecine Ii , 34184 Montpellier Cedex 4
France

Telephone +33 (0)467 419748
Fax +33 (0)467 457726
info@acobiom.com

This company is co-exhibitor of
Business France

Trade fair hall

  • Hall 15 / C55
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 15): stand C55

Fairground map

MEDICA 2016 fairground map: Hall 15

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Our products

Product category: Gene tests / molecular biological diagnostic

A New In Vitro Diagnostic to predict response to Gemcitabine treatment in pancreatic cancer

Acobiom proposes a new In Vitro Diagnostic Multivariate Index Assay (IVDMIA), based on a new Blood RNA-biomarker signature, able to predict response to Gemcitabine (Gemzar) in Metastatic Pancreatic Cancer and to prognose a 14.9-month survival.
Acobiom discovered and patented a new innovative set of biomarkers identified through Omics and BIG DATA performed on blood samples that are correlated to a 14.9-month survival prognosis in Pancreatic Cancer patients treated by Gemcitabine.

This new In Vitro Diagnostic Multivariate Index Assay (IVDMIA) based on qRT-PCR technology, called GemciTest, is now available and can be ordered for « research use only ».

The benefits of GemciTest on clinical and economical aspects are described on the following document: the GemciTest flyer.

Moreover, regulatory queries are currently under review to obtain a CE mark, and a Pre-submission Request filed by Acobiom concerning its GemciTest is currently under review by FDA.

These results have recently been presented at a Cancer-Bio-Santé meeting (Toulouse, France, 8th of october 2015; see the GemciTest presentation) and at the « first Pancreatic Cancer Symposium » (Marseille, France, 28-30 october 2015, www.pcs-2015.com; see the GemciTest Poster).

More Less

Product category: Gene tests / molecular biological diagnostic

Diagnostics dedicated to Translational Medicine, Personalized Medicine, or Precision Medicine.

Acobiom is involved in the development of innovative and non-invasive Diagnostics dedicated to Translational Medicine, Personalized Medicine, or Precision Medicine. Hence, the company has already developed In Vitro Diagnostic Assays based on New Blood Biomarkers in order to predict response to specific treatment or to prognose clinical evolution of patients.

Due to its expertise in Next-Generation Sequencing (NGS) technologies, genomics, transcriptomics and bioinformatics, Acobiom is currently involved in several developments concerning Personalized Medicine, Companion Diagnostics and patient stratification tests, which will enable stratifying or segmenting patients according to typical profiles or phenotypes.

Hence, two In Vitro Assays based on qRT-PCR technology are available for clinicians for Research Use Only (RUO):
> a Diagnostic to predict response to Gemcitabine (Gemzar) treatment in Metastatic Pancreatic Cancer and to prognose a 15-months survival,
> a Diagnostic to prognose a positive 4-year survival in Chronic MyeloMonocytic Leukemia,

Other several innovative healthcare solutions are under clinical development in Cancer and Alzheimer’s disease.

If you need more information, please contact our Business Development Department
(T: +33(0)467 419 748, Email: info@acobiom.com)

More Less

Product category: Gene tests / molecular biological diagnostic

Personalized Medicine

Acobiom is specialized in the discovery of new Biomarkers and the development of innovative and non-invasive Diagnostics dedicated to Translational Medicine, Personalized Medicine, or Precision Medicine.

Acobiom is positioned in the field of “Personalized Medicine,” which takes people’s biological and physiological differences into account in order to administer the most effective treatment, the most adapted treatment that matches the patient profile. The company’s products include Diagnostics such as “patient stratification” tests and Companion Diagnostics that enable stratifying and segmenting patients according to “typical profiles » or to « predictive response to a specific treatment ».

Personalized Medicine
Acobiom is involved in personalized medicine due to its Omics expertise enabling to identify new Biomarkers associated with gene expression – phenotype – changes. The company is working towards developing daily practice In Vitro Diagnostics on the basis of new identified RNA Blood Biomarkers.

A patient’s response to a specific treatment may not simply be determined by a single gene, but by a combination of several genes and their interacting products. Acobiom’s biomarkers can meet this challenge in personalized medicine.

The biomarkers identified in this way by Acobiom can be used for:

- Diagnosing diseases or predicting risks of disease,
- Determining whether a treatment is efficient or not,
- Monitoring healthy people to detect early signs of disease,
- Producing safer drugs by predicting the potential for adverse effects earlier,
- Targeting specific groups of people for whom a particular drug may be useful, while not using it for those for whom it may prove harmful,
- Providing researchers with the opportunity of having a global view of the events and changes that are always occurring within a cell.

More Less

About us

Company details

Our core business: Biomarkers & Diagnostics
Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and the development of innovative diagnostics.

Acobiom’s business model is based on two main activities:

(1) developing and commercializing diagnostics and companion diagnostics (CDx), notably for personalized medicine applications;

(2) providing services in the fields of genomics, pharmacogenomics, and transcriptomics, for research purposes and clinical trials.

To reach its objectives, the company has developed and continually refined a technology platform for identifying biomarkers associating high-throughput technologies (sequencing, NGS, qRT-PCR), and proprietary bioinformatic and biostatistical tools.

Acobiom decided to invest the personalized medicine field in developing innovative diagnostics to adapt treatment to patients, especially in oncology, infectiology and neurodegenerative diseases.

For its service business, Acobiom has been granted a Research Tax Relief (« Agrément Crédit Impôt Recherche ») by the French Ministry of Research and Technology, enabling industry clients to apply the company’s services to their research tax credits.

If you require any additional information concerning our company, please contact our corporate department: +33(0)467 419 748.

More Less